Investors aren’t the only ones burned by misleading drug company news releases
‘Overwhelming efficacy’ or ‘tiny effect size’? Bayer’s data-free claims on blood-thinner study extend troubling PR trend
Is it ok for journalists to attend Bayer-funded training on new cancer treatments?
Better late than never, FDA to hold long overdue safety hearing on Essure sterilization device